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Objective. Remission in rheumatoid arthritis
(RA) is an increasingly attainable goal, but there is no
widely used definition of remission that is stringent but
achievable and could be applied uniformly as an out-
come measure in clinical trials. This work was under-
taken to develop such a definition.
Methods. A committee consisting of members of
the American College of Rheumatology, the European
League Against Rheumatism, and the Outcome Mea-
sures in Rheumatology Initiative met to guide the
process and review prespecified analyses from RA clin-
ical trials. The committee requested a stringent defini-
tion (little, if any, active disease) and decided to use core
set measures including, as a minimum, joint counts and
levels of an acute-phase reactant to define remission.
Members were surveyed to select the level of each core
set measure that would be consistent with remission.
Candidate definitions of remission were tested, includ-
ing those that constituted a number of individual mea-
sures of remission (Boolean approach) as well as defi-
nitions using disease activity indexes. To select a
definition of remission, trial data were analyzed to
examine the added contribution of patient-reported
outcomes and the ability of candidate measures to predict
later good radiographic and functional outcomes.
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Results. Survey results for the definition of remis-
sion suggested indexes at published thresholds and a
count of core set measures, with each measure scored as 1
or less (e.g., tender and swollen joint counts, C-reactive
protein [CRP] level, and global assessments on a 0–10
scale). Analyses suggested the need to include a patient-
reported measure. Examination of 2-year followup data
suggested that many candidate definitions performed com-
parably in terms of predicting later good radiographic and
functional outcomes, although 28-joint Disease Activity
Score–based measures of remission did not predict good
radiographic outcomes as well as the other candidate
definitions did. Given these and other considerations, we
propose that a patient’s RA can be defined as being in
remission based on one of two definitions: (a) when scores
on the tender joint count, swollen joint count, CRP (in
mg/dl), and patient global assessment (0–10 scale) are all
<1, or (b) when the score on the Simplified Disease
Activity Index is <3.3.
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remission, both of which can be uniformly applied and
widely used in RA clinical trials. We recommend that one
of these be selected as an outcome measure in each trial
and that the results on both be reported for each trial.
With the advent of new therapies and treatment
strategies for rheumatoid arthritis (RA), remission has
become a realistic goal (1–3) and has recently become a
secondary or even primary end point for clinical studies
and trials (4–8). Remission is also regarded as a major
therapeutic target in clinical practice (9–12) and can be
achieved in a significant proportion of patients receiving
routine followup care (13–15). However, the formal
definition of RA remission differs between studies.
The current American College of Rheumatology
(ACR) definition of remission in RA (16) was developed
in 1981, prior to the introduction of the RA core set
measures (17). In this classic article, Pinals et al stated:
“. . . ‘complete remission’ implies the total absence of all
articular and extraarticular inflammation and immuno-
logic activity related to rheumatoid arthritis (RA).”
Recognizing that detecting such a state could entail
documentation by “extraordinary measures,” they set-
tled on the concept of “complete clinical remission,”
aiming to achieve “uniformity in clinical application
using generally acceptable and convenient measures.”
Even though this concept is of considerable value as a
therapeutic target in trials and clinical practice, the 1981
ACR definition has not been widely used in clinical trials
in RA because it contains some elements not in the core
set (morning stiffness, swelling in tendon sheaths) and a
time requirement. Also, this original version was so
stringent that few patients met the criteria. Subse-
quently, many modifications of the ACR criteria were
developed, usually omitting one or more of the measures
as well as the time requirement.
The development of composite indices of disease
activity allowed definition of cut point values represent-
ing remission (18–20), but their validation was often
limited to comparisons with such modified ACR criteria.
For instance, we now know that the widely used defini-
tion of remission based on a 28-joint Disease Activity
Score (DAS28) (21) of 2.6 (18) better represents
minimal disease activity than remission, since multiple
joints can remain swollen or tender at that score (19,22–
24). This is further exemplified by the fact that in many
recent clinical trials the proportion of patients with an
ACR70 response (i.e., improvement based on the ACR
preliminary definition of improvement [25] but applying
70% improvement instead of 20%) is similar to, or even
lower than, the proportion of patients attaining remis-
sion as assessed by the DAS28 (5,26–28). Thus, the 1981
statement by Pinals et al (16) remains relevant today:
“Substantial variation appears to exist in the concept
of remission within the group of participating rheuma-
tologists.”
In the meantime, effective treatments for RA
have led to more exacting criteria for improvement (e.g.,
ACR 50%, 70%, and even 90% improvement) and have
led to recently proposed definitions of minimal disease
activity (29). In light of the heterogeneity of definitions
of remission, the time has come for consensus on a new,
uniform remission definition. Therefore, the ACR and
the European League Against Rheumatism (EULAR),
together with the Outcome Measures in Rheumatology
Initiative (OMERACT), jointly convened a committee
to redefine remission in RA. This committee subse-
quently published a systematic review of the prognostic
validity of current remission definitions (30) as well as
an outline of the goals of redefining remission and the
methods by which the goals would be attained (2).
At noted in this already published outline of our
goals (2), the committee decided by consensus to create
a stringent definition for remission and agreed that any
definition should include, as a minimum, tender and
swollen joint counts and levels of an acute-phase reac-
tant. Excluded were treatment, duration of remission
(the committee believed this should be specified in each
trial report), and measures of physical function and
radiographic damage. The latter two were to be used to
validate candidate remission definitions: the chosen
definition should predict future good functional out-
comes and absence of radiographic damage progression.
Remission should also predict future remission and
minimal disease activity, i.e., show stability. Finally, the
requirement for full or 28-joint counts had to be studied.
The committee suggested that core set measures should
be used to define remission and that any definition of
remission in clinical trials should look toward and make
possible a similar definition in clinical practice.
The selection of the optimal definition of remis-
sion was guided by the research agenda as put forth by
the committee at the beginning of our deliberations. In
general, the evidence-based consensus method was in
accordance with similar activities previously performed
by OMERACT as well as ACR and EULAR (31–33)
with the intent of deriving a definition that would pass
the OMERACT filter of truth, discrimination, and fea-
sibility (34). Herein we present the results of analyses
addressing this research agenda, report on later meet-
ings of the committee in which the results were evalu-
ated, and present a consensus definition of remission.
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METHODS
General aspects. The initial committee was formed by
inviting members of the ACR committee that had previously
formulated the new ACR response criteria (35), principal
investigators of recent clinical trials, methodologists and pa-
tient experts from the OMERACT community, and ACR,
EULAR, and OMERACT leaders, with a view to being
inclusive and geographically representative. All members
present at one of the committee meetings were asked to
consider becoming authors of the present report. A patient
expert (or research partner) can be described as a patient
involved in research based on personal experience of disease
that is not available to most researchers, but that complements
researchers’ analytical skills and scientific perspective (36).
During the development of the remission definition, 6 patient
experts were involved, 3 of whom (MdW, PM, PR) are authors.
Using the specifications provided by the committee, a steering
group (DTF, JSS, GW, BZ, LHDvT, JF, MB) designed and
performed the necessary investigations; this included a survey
as well as analyses of clinical trial data. Clinical trial data banks
with slightly different total patient numbers and data compo-
sition were created at different centers. Because industry-
funded clinical trials have been the largest RA trials carried
out and data collected in these trials would be useful for testing
hypothesized remission definitions, we solicited industry-
funded RA clinical trials data, with the companies’ approval.
Industry had no role in data analysis, criteria development,
testing or evaluating the process, or final choices made by the
committee, nor were they consulted or involved in manuscript
development. These data were analyzed by the steering group
according to the committee’s specifications and methodologic
discussions in the steering group.
Survey. Our first goal in selecting candidate criteria for
remission was to define what cut points in each of the core set
measures might constitute remission. In a survey we asked
committee members (experienced RA clinical researchers and
patient experts) what level of residual activity in individual
core set measures would constitute remission. For all measures
except joint counts, we used a 0–10 scale. For C-reactive
protein (CRP), we used a scale in milligrams per deciliter. For
initial analyses of joint counts, we used a 28-joint count and
then examined its validity for remission (see below). We asked
committee members to state the highest level of each core set
measure that would be compatible with remission if it were the
only measure assessed, and also asked for the highest level of
a particular core set measure that would be compatible with
remission if all other measures suggested remission.
Value of patient-reported outcomes. The committee
raised the question as to whether patient-reported outcomes
should be included in the definition of remission. We ad-
dressed this issue by asking whether patient-reported out-
comes at the level of remission discriminated between active
versus control treatment in trials. In a subset of our data bank,
which comprised core set data from 4 clinical trials (37–40), we
performed two sets of analyses in each trial. In both analyses
the dependent variable was treatment assignment. First, we
carried out a logistic regression with each of the core set
measures as predictors (recoded as remission level, e.g., swol-
len joint count1: yes or no). Second, we performed recursive
partitioning by classification and regression tree (CART)
analysis on data from the 4 clinical trials, in which we ranked
core set measures at remission level based on the tree created
from a series of binary splits. Recursive partitioning is a
statistical method for multivariable analysis, creating a tree
with branches that strives to correctly classify members of the
population based on a dichotomous dependent variable. If the
patient-reported outcomes helped differentiate active treat-
ment from control (either by being a significant predictor in
the regression analysis or by having a high rank in the
classification tree), then these outcomes would be said to
contribute importantly to defining remission. Patient-reported
outcomes tested in this analysis were patient global assessment
and patient pain. Functional status measurement was not
included, for reasons outlined above.
Assessment of predictive validity. Once we had de-
cided that patient-reported outcomes were to be included and
had determined the cut points to be used to define remission,
we undertook the analysis of predictive validity. To this end we
evaluated various 2-year data sets from randomized clinical
trials (patient-level data on 80–90% of patients selected ran-
domly) kindly provided by the sponsors of these studies
(35,37,40–43) and obtained permission to use these data for
the present analysis. The data are described in more detail in
the original publications. For the present analyses, we evalu-
ated only patients for whom all pertinent data over a 2-year
period were available.
We initially defined good outcome for radiographic
damage and physical function separately. For radiographic
damage, the definition comprised stable radiography scores
over 1 year (defined as change of 0 in Sharp scores [44] or
modified Sharp/van der Heijde scores [45] during the second
year of the trial). For physical function, it comprised stable and
low scores on the Health Assessment Questionnaire (HAQ)
(46) (change of 0 and HAQ score consistently 0.5 during
the second year of the trial). We then tested whether patients
who met a particular definition of remission at 6 months or 12
months were more likely to have a good outcome in the
subsequent period, i.e., between 1 and 2 years after trial
initiation. Likelihood ratios were used to compare the propor-
tion of patients having the good outcome whose RA was in
remission to the proportion of patients having the good
outcome whose RA was not in remission. To rank candidate
definitions of remission, we used the P value from the logistic
regression chi-square test. As has been reported (47), most
patients in trials who are followed up long term do not show
radiographic progression. This limited our capacity to discrim-
inate between candidate definitions of remission. Moreover,
intensive therapy with tumor necrosis factor (TNF) inhibitors
plus methotrexate (MTX) dissociates clinical disease activity
from progression of joint damage, since—unlike patients
treated with MTX alone—those receiving aggressive treat-
ments have no or minimal radiographic progression irrespec-
tive of their disease activity (48–50). Therefore, we primarily
performed the analyses on patients treated with MTX mono-
therapy; however, we also evaluated TNF inhibitor mono-
therapy and combination therapy in sensitivity analyses. To
assess the robustness of the results, we also performed the
analyses on a subset of trial patients with an especially poor
prognosis in terms of radiographic disease—i.e., presence of
rheumatoid factor and presence of radiographic damage at
baseline. Finally, we tested an additional definition of a good
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outcome, i.e., stability of both radiographic damage and HAQ
score.
Selection of candidate definitions. Candidate defini-
tions of remission were selected from two general categories:
first, indices that have been widely used, including the DAS28,
the Simplified Disease Activity Index (SDAI), and the Clinical
Disease Activity index (CDAI) (18,19,21,32,33,51,52), and
second, definitions including one or more core set measures at
cut points previously defined by the survey, but requiring all
included measures to be at or below that cut point. For
example, to meet remission defined as low scores on tender
and swollen joint counts and physician and patient global
assessments, the patient must have had low scores on all 4
measures. These measures are referred to below as the Bool-
ean measures based on their approach, which is to define each
core set measure as in remission or not (values of 0 and 1) and
use possible combinations of the patient’s core set measure
remission status to determine the patient’s overall remission
status (also 0 or 1).*
Further evaluations of candidate definitions including
assessment of face validity. After completing the analysis of
predictive validity, we tested our candidate definitions for face
validity. Since we had decided that any definition of remission
must be stringent with respect to not allowing much disease
activity, we studied whether patients could meet a definition of
remission yet still have moderate to high levels of disease
activity in any core set measure. To do this, in the group of
patients meeting a certain definition of remission, we studied
the 90th percentile and maximum level of disease activity
observed in each core set measure. Last, we looked at recent
trial data to determine what proportion of patients met each
remission definition. It was our goal not to have an undetect-
ably low percentage of patients meeting the definition of
remission, or one so high as to be unreasonable given clinical
experience with these treatments.
We also examined two related issues for our candidate
definitions. First, we wished to select a definition(s) that was
reliable, and we determined this by analyzing, in one trial with
monthly visits, whether a patient whose RA was defined as
being in remission at one visit attained the same status at
adjacent visits 1 month from the first; if the disease was not
in remission at the adjacent visit, we assessed whether disease
activity remained at minimal levels (29). Second, we were
concerned that a 28-joint count might not capture actively
involved joints outside these 28; to address this, we reviewed
literature and analyzed trial data to determine whether we
should define remission differently when using 28 versus, for
example, 66 joints. For the latter, we evaluated data from a set
of trials that included tenderness and swelling counts of
individual joints. In these we assessed residual disease activity
in ankles and feet in patients with 28-joint counts of 1 and
determined what proportion of such patients would satisfy the
other requirements of our candidate definitions. These pa-
tients would represent real misclassification (“false-positive”
remissions). In the same data set we subsequently investigated
whether such misclassification could materially affect the
predictive validity of the remission definitions. For this pur-
pose we compared the prevalence of good outcome (damage
or function) in patients with “true remission” (i.e., based on
full joint counts at 1) with that in all patients with remission
based on 28-joint counts (i.e., “true” plus “false-positive”
remissions).
RESULTS
Survey. Twenty-seven committee members, in-
cluding two patients, completed the survey on threshold
levels for remission (Table 1). In the scenario in which
*Boolean measure is the logic that computers use to deter-
mine if a statement is true or false. There are 4 main Boolean
operators: AND, NOT, OR, and XOR (exclusive OR). Below is an
example, from defining remission, of how one operator works:
Assume that x and y are both core set variables for RA whose
values are in the range of remission. x AND y returns True if both x
and y are true; otherwise the expression returns False. False means
that patient’s RA is NOT in remission.
Table 1. Threshold levels for remission in the RA core set measures according to the survey of committee members*
Core set measure
Highest level of the core set measure that would be compatible with remission
If it were the only measure assessed If all other measures suggested remission
Mean  SD Minimum Median 80% Maximum Mean  SD Minimum Median 80% Maximum
TJC28 1.1 1.3 0 1 2 6 2.6  2.0 1 2 4 10
Full TJC (68 joints) 1.6  1.5 0 2 2 6 2.6  2.0 1 2 4 10
SJC28 0.5 0.9 0 0 1 4 1.3  1.3 0 1 2 6
Full SJC (66 joints) 0.6  0.9 0 0 1 4 1.4  1.2 0 1 2 6
ESR, mm/hour 21 6 10 20 25 30 25  6 20 25 30 40
CRP, mg/dl 0.9  0.4 0 1 1 2 1.1  0.6 0 1 1.5 2
Pain, 010 scale 1.3  0.7 0 1 2 3 2.4  1.3 1 2 3 6
PhGA, 010 scale 1.0  0.9 0 1 1 4 1.6  1.0 0 2 2 4
PtGA, 010 scale 1.2  0.8 0 1 2 3 2.2  1.3 0 2 3 6
HAQ, 0–3 scale 0.7 0.7 0 0.5 0.5 3 0.9  0.8 0.2 0.6 1 3
* Twenty-seven committee members responded to the survey (25 experienced rheumatoid arthritis clinical researchers and 2 patients). RA 
rheumatoid arthritis; 80%  80th percentile; TJC28  tender joint count using 28 joints; SJC  swollen joint count using 28 joints; ESR 
erythrocyte sedimentation rate; CRP  C-reactive protein; PhGA  physician/observer global assessment; PtGA  patient global assessment;
HAQ  Health Assessment Questionnaire.
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only one variable was available, the responses clustered
around core set disease activity levels of 1, such that, for
example, the swollen or tender joint count should be 1 or
less, the CRP level should be 1 mg/dl or less, and patient
and physician global assessments as well as patient pain
assessment should be 1 or less on a 10-point scale. The
question on which was the highest level of a particular
core set measure compatible with remission if all other
measures suggested remission yielded more varied an-
swers, with thresholds ranging from 2 for swollen joint
count (SJC) and CRP level to 4 for tender joint count
(TJC). Since this did not provide us with a single
threshold value that was uniform across core set mea-
sures, we focused on the more stringent cut points.
Patient-reported outcomes. We then proceeded
with an analysis of clinical trial data on active treatment
versus control to help determine whether patient-
reported outcomes, namely patient global assessment or
patient-reported pain, should be incorporated into our
definition of remission. In an analysis of 4 clinical trials,
both logistic regression and CART analysis demon-
strated that these measures added important informa-
tion to physician-linked measures. In other words, in
these trials, patient global assessment and patient-
reported pain were statistically significant predictors
that discriminated between treatments after controlling
for physician-reported measures (TJC and SJC) and a
laboratory measure (CRP). For example, in the CART
analysis, among the 4 trials, patient global assessment
was the best predictor of treatment assignment among
all outcomes in one trial and the fourth best of core set
measures in another. Patient-reported pain was the
second best predictor (SJC was the best) in a third trial.
Based on these preliminary analyses, we devel-
oped a list of candidate remission definitions to test for
predictive validity. When presented with the more strin-
gent definitions versus the more relaxed definitions, our
committee selected those in the more stringent category
and as a consequence, we present results only for these.
In accordance with the committee’s charge and the
assessment of the contribution of patient-reported out-
comes, we mainly focused on measures that comprised
TJC, SJC, CRP level, and patient global assessment. We
tested combinations of these and other core set mea-
sures to determine if any group of measures would have
important advantages.
Table 2. Predictive validity of candidate remission definitions for good outcome in radiographic damage*
Candidate remission definition








TJC28, SJC28, CRP 1 69 (34/49) 50 (154/306) 2.0 (1.13.6) 0.01
TJC28, SJC28, CRP, PhGA 1 76 (26/34) 51 (162/320) 2.9 (1.36.2) 0.004
TJC28, SJC28, CRP, PtGA 1 77 (23/30) 51 (165/325) 2.9 (1.36.6) 0.006
TJC28, SJC28, CRP, pain 1 74 (23/31) 51 (165/324) 2.6 (1.25.6) 0.01
TJC28, SJC28, CRP, PhGA, PtGA 1 77 (20/26) 51 (168/328) 2.9 (1.27.2) 0.01
TJC28, SJC28, CRP, PhGA, pain 1 77 (20/26) 51 (168/328) 2.9 (1.27.2) 0.01
TJC28, SJC28, CRP, PtGA, pain 1 76 (22/29) 51 (166/326) 2.8 (1.26.4) 0.001
TJC28, SJC28, CRP, PhGA, PtGA, pain 1 76 (19/25) 51 (169/329) 2.8 (1.16.8) 0.02
DAS28 2.6 60 (21/35) 59 (93/157) 1.0 (0.61.9) 0.93
DAS28 2.0 70 (7/10) 59 (107/182) 1.6 (0.46.0) 0.48
SDAI 3.3‡ 77 (27/35) 50 (161/319) 3.0 (1.46.4) 0.003
Definitions without CRP (for clinical practice)
TJC28, SJC28, PhGA, PtGA 1 75 (24/32) 51 (167/326) 2.6 (1.25.7) 0.01
TJC28, SJC28, PtGA 1 75 (27/36) 51 (164/323) 2.6 (1.35.4) 0.007
CDAI 2.8§ 75 (27/36) 51 (164/322) 2.6 (1.35.4) 0.006
* Values in the first 2 columns are percentages, with absolute proportions shown in parentheses. Presence or absence of
remission, defined according to the given candidate definition, was measured at 6 months after baseline, using combined data
from methotrexate-alone treatment groups in 3 trials (37,40,41) (limited to patients with complete data over 2 years). Good
radiographic outcome was defined as a change of 0 in Sharp/van der Heijde scores between 12 and 24 months after baseline.
CRP is in mg/dl. 95% CI  95% confidence interval; DAS28  28-joint Disease Activity Score (see Table 1 for other
definitions).
† From chi-square analysis using logistic regression, in which the independent variable was remission (based on the given
candidate definition) and the dependent variable was radiographic stability.
‡ The Simplified Disease Activity Index (SDAI) is the simple sum of the TJC (using 28 joints), SJC (using 28 joints), patient
global assessment (010 scale), physician global assessment (010 scale), and CRP level (mg/dl).
§ The Clinical Disease Activity Index (CDAI) is the same as the SDAI, except CRP is not included.
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Predictive validity. We then tested whether pa-
tients whose RA was in remission according to one of
these definitions had a higher likelihood of a good
outcome. We focused on patients receiving MTX mono-
therapy, although we obtained similar results (not
shown) when we analyzed data from all patients. We
found that patients whose RA was in remission by
several of the Boolean candidate definitions, as well as
by the traditional SDAI definition (3.3) and CDAI
definition (2.8), had an increased likelihood of
radiographic stability during the subsequent year
(Table 2). However, this was not the case for the DAS28
definition, either at the traditional cut point (2.6) or at
a more stringent cut point (2.0). In contrast, being in
remission by any of the definitions increased the likeli-
hood of stability on HAQ scores, without important
differences between definitions (data not shown). When
we defined good outcome as the combination of radio-
graphic and HAQ stability, we again found that being in
remission by any of the candidate definitions increased
the likelihood of a good outcome (Table 3). As expected,
the performance of the DAS28 at either cutoff was not
as good as that of the other definitions. Similar data
were also obtained in an additional data set from the
COBRA (Combinatietherapie Bij Reumatoı¨de Artritis)
study (42) (data not shown). However, reaching remis-
sion according to the DAS28, both at the traditional cut
point (2.6) and at a more stringent cut point (2.0),
was associated only with the likelihood of HAQ stability,
and not radiographic stability. Candidate definitions of
remission did not differ in their prediction of HAQ
stability (data not shown). Additional definitions were
tested, including incorporating either remission-level
pain or patient global assessment and other variations,
and results were similar. Apart from the DAS28 result,
the analyses did not help to distinguish between defini-
tions. This was also the case in the analysis using a more
strict definition of good outcome, and when we studied
only patients with a poor prognosis (data not shown).
Face validity. Face validity of the different can-
didate definitions, expressed as residual disease activity
in the presence of remission, is shown in Table 4. For the
Boolean definitions, the high values, as expected, tended
to be for core set measures that were not prespecified by
the rule. For example, if we used the definition of TJC,
SJC, CRP, and pain all 1, we found that 10% of
Table 3. Predictive validity of candidate remission definitions for good outcome in both radiographic damage and HAQ*
Candidate remission definition








TJC28, SJC28, CRP 1 46 (22/48) 17 (51/301) 3.2 (1.95.3) 0.0001
TJC28, SJC28, CRP, PhGA 1 55 (18/33) 17 (55/315) 4.5 (2.48.5) 0.0001
TJC28, SJC28, CRP, PtGA 1 66 (19/29) 17 (54/320) 7.2 (3.514.8) 0.0001
TJC28, SJC28, CRP, pain 1 60 (18/30) 17 (55/319) 5.7 (2.911.2) 0.0001
TJC28, SJC28, CRP, PhGA, PtGA 1 68 (17/25) 17 (56/323) 8.0 (3.617.8) 0.0001
TJC28, SJC28, CRP, PhGA, pain 1 64 (16/25) 18 (57/323) 6.7 (3.114.5) 0.0001
TJC28, SJC28, CRP, PtGA, pain 1 64 (18/28) 17 (55/321) 6.8 (3.314.1) 0.0001
TJC28, SJC28, CRP, PhGA, PtGA, pain 1 67 (16/24) 18 (57/324) 7.5 (3.416.9) 0.0001
DAS28 2.6 38 (13/34) 18 (28/154) 2.2 (1.24.0) 0.01
DAS28 2.0 56 (5/9) 20 (36/179) 4.5 (1.315.9) 0.01
SDAI 3.3‡ 56 (19/34) 17 (54/314) 4.8 (2.68.9) 0.0001
Definitions without CRP (for clinical practice)
TJC28, SJC28, PhGA, PtGA 1 68 (21/31) 17 (53/321) 7.9 (3.916.0) 0.0001
TJC28, SJC28, PtGA 1 66 (23/35) 16 (51/318) 7.2 (3.813.9) 0.0001
CDAI 2.8§ 63 (22/35) 16 (52/317) 6.4 (3.412.0) 0.0001
* Values in the first 2 columns are percentages, with absolute proportions shown in parentheses. Presence or absence of
remission, defined according to the given candidate definition, was measured at 6 months after baseline, using combined data
from methotrexate-alone treatment groups in 3 trials (37,40,41) (limited to patients with complete data over 2 years). Good
radiographic outcome was defined as a change of 0 in Sharp/van der Heijde scores between 12 and 24 months after baseline;
good outcome on the HAQ was defined as a change of0 and a score of0.5 at both the 12-month and 24-month time points.
CRP is in mg/dl. 95% CI  95% confidence interval; DAS28  28-joint Disease Activity Score (see Table 1 for other
definitions).
† From chi-square analysis using logistic regression, in which the independent variable was remission (based on the given
candidate definition) and the dependent variable was the combination of radiographic and HAQ stability.
‡ The Simplified Disease Activity Index (SDAI) is the simple sum of the TJC (using 28 joints), SJC (using 28 joints), patient
global assessment (010 scale), physician global assessment (010 scale), and CRP level (mg/dl).
§ The Clinical Disease Activity Index (CDAI) is the same as the SDAI, except CRP is not included.
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patients (90th percentile) had physician and patient
global assessment scores compatible with active disease.
If we used TJC, SJC, and CRP all 1, then the
patient-reported outcomes often suggested high levels of
symptoms. For the traditional DAS28 definition (2.6),
we found that many of the core set measures remained
at levels that would be incompatible with remission. This
was even the case for DAS28 2.0, which was a thresh-
old few patients reached. It was not the case for other
index measures that defined remission, such as the SDAI
or CDAI, where results were closely aligned with the
Boolean definitions and the results of our survey.
When we examined the proportion of patients in
trials who met candidate definitions of remission (Table
5), we felt that the high prevalence of remission accord-
ing to the current DAS28 definition lacked face validity.
Otherwise, 18–26% of patients receiving combination
therapy with TNF inhibitors and MTX met most of these
definitions, compared to only 5–10% of those receiving
either monotherapy. We believe these percentages re-
flect face validity.
Consensus activity. The committee met prior to
the ACR Annual Scientific Meeting in October 2009 to
discuss the analyses described above. As noted, the
committee did not select, in any case, a more relaxed
definition of remission, consistent with its earlier direc-
tive. During the committee meeting two subgroups were
formed to discuss the tabular results presented, espe-
cially including results regarding predictive validity.
Both groups voted that there should be both a Boolean
approach and an index-based definition. One group
voted among individual definitions of remission, and in
doing so, the highest vote was received for the Boolean
definition that included TJC, SJC, CRP, and patient
global assessment, all at levels 1. The index definition
with the highest vote count was SDAI 3.3. In the other
Table 4. Face validity expressed as residual disease activity in the presence of remission*
Candidate remission definition
TJC28 SJC28 CRP PhGA PtGA Pain
90% Max 90% Max 90% Max 90% Max 90% Max 90% Max
TJC28, SJC28, CRP 1 1 1 1 1 0.6 1 2 6 4 8 4 8
TJC28, SJC28, CRP, PhGA 1 1 1 1 1 0.6 1 1 1 2 7 2 8
TJC28, SJC28, CRP, PtGA 1 1 1 1 1 0.6 1 2 2 1 1 2 3
TJC28, SJC28, CRP, pain 1 1 1 1 1 0.6 1 2 4 2 6 1 1
TJC28, SJC28, CRP, PhGA, PtGA 1 1 1 1 1 0.7 1 1 1 1 1 1 3
TJC28, SJC28, CRP, PhGA, pain 1 1 1 1 1 0.7 1 1 1 1 5 1 1
TJC28, SJC28, CRP, PtGA, pain 1 1 1 1 1 0.7 1 1 2 1 1 1 1
TJC28, SJC28, CRP, PhGA, PtGA, pain 1 1 1 1 1 0.7 1 1 1 1 1 1 1
DAS28 2.6 2 7 4 21 0.7 2.5 2 5 3 8 2 10
DAS28 2.0 0 3 2 6 0.7 2.5 2 3 2 4 2 4
SDAI 3.3 1 2 1 2 0.7 2.7 2 2 1 2 1 3
* Values are the upper limits of residual disease activity in the RA core set measures for candidate definitions of remission observed in trial data
sets using all trial arms (methotrexate monotherapy, tumor necrosis factor inhibitor monotherapy, and combination therapy with tumor necrosis
factor inhibitors plus methotrexate). CRP is in mg/dl. 90%  90th percentile; Max  maximum observed value; DAS28  28-joint Disease Activity
Score; SDAI  Simplified Disease Activity Index (see Table 1 for other definitions).













TJC, SJC, CRP, PtGA 1 9 7 22 12
TJC, SJC, CRP, PtGA, pain 1 8 6 20 12
TJC, SJC, CRP, PhGA, PtGA 1 8 7 20 10
TJC, SJC, CRP, PhGA, pain 1 8 6 20 10
TJC, SJC, CRP, PhGA, PtGA, pain 1 7 6 18 9
DAS28 2.6 19 17 35 21
DAS28 2.0 5 8 24 10
SDAI 3.3 10 8 26 14
* From pooled data from refs. 37, 40, and 41. CRP is in mg/dl. DAS28  28-joint Disease Activity Score; SDAI  Simplified
Disease Activity Index (see Table 1 for other definitions).
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subgroup, after a discussion involving all study group
members, the same conclusion was reached without a
formal vote.
Members of this subgroup noted that in the clinical
setting an acute-phase response measure is often not
available at every visit and the subgroup suggested that a
definition of remission be developed for clinic-based prac-
tice that would not require an acute-phase reactant, as long
as it would capture remission as stringently as the measure
used for clinical trials. Indeed, a Boolean measure com-
prising TJC, SJC, and patient global assessment provided
statistical results similar to those obtained with the same
measures encompassing CRP and those obtained with the
CDAI, which does not include CRP (Table 2). Thus, these
definitions of remission may be used in clinical practice
until better measures for that purpose become available.
In a trial with monthly visits we found that our
selected definitions of remission showed good reliability.
Specifically, among patients whose RA was in remission
at one time point, the disease remained in remission 1
month later in 66%, and all the rest met criteria for
minimal disease activity (29).
Joint counts. We consulted published literature
and our own data analysis to determine if remission
thresholds for 28-joint counts should be the same as
thresholds for counts with more joints assessed (such as
66 or 68 joints). One study (53) examined whether
adding ankles and metatarsophalangeal joints to the
28-joint count affected remission and showed that
10% of patients with no tender or swollen joints in a
28-joint count had tender or swollen ankles or metatar-
sophalangeal joints and that the average patient global
assessment score in these latter patients was significantly
higher, suggesting that they would not meet proposed
definitions of remission. Landewe´ and colleagues (24)
also noted that defining a patient’s disease as being in
remission using a 28-joint count often concealed active
joints elsewhere, especially in the feet and ankles. How-
ever, they also reported that global assessments for
patients who had 28 joints in remission but actively
involved joints elsewhere resembled those for patients
whose disease was not in remission based on a 28-joint
count, suggesting that requiring a low patient global
assessment score will, to some extent, mitigate the
limitation of using a 28-joint count.
In the two trials in our data set that included
counts of individual joints with tenderness and swelling,
remission prevalence using 66 and 68 joints was 4% and
9%, respectively. As in the studies cited above, we found
that patients with 28-joint counts 1 often had residual
tenderness or swelling in the ankles or feet. However,
most of these patients did not satisfy the other require-
ments of our candidate definitions of remission. Never-
theless, the estimates of remission prevalence increased
to 6% and 14%, respectively, of the total population
when 28-joint counts were used. In another data set from
two trials with 2-year followup data, we compared
patients whose RA was in remission according to full
(66/68) joint counts versus those whose RA was in
remission according to only 28-joint counts (i.e., with
residual disease activity in joints not assessed). Among
the patients with “full joint count remission,” 80% had
good outcomes in terms of radiographic damage (no
change in Sharp score); this number decreased by 1%
among patients with only “28-joint count remission.”
Likewise, among the patients with “full joint count
remission,” 90% had good HAQ outcomes; this number
decreased by 1% and 4%, respectively, in the 2 trials,
among patients with only “28-joint count remission.”
Based on these analyses we concluded that the overall
impact (misclassification) due to reduced joint counts is
small.
The final recommended definitions of remission
are presented in Table 6. Specific suggestions on how
Table 6. American College of Rheumatology/European League
Against Rheumatism definitions of remission in rheumatoid arthritis
clinical trials*
Boolean-based definition:
At any time point, patient must satisfy all of the following:
Tender joint count 1†
Swollen joint count 1†
C-reactive protein 1 mg/dl
Patient global assessment 1 (on a 0–10 scale)‡
Index-based definition:
At any time point, patient must have a
Simplified Disease Activity Index score of 3.3§
* See text and Tables 2 and 3 for recommendations regarding assess-
ment of remission in clinical practice settings.
† For tender and swollen joint counts, use of a 28-joint count may miss
actively involved joints, especially in the feet and ankles, and it is
preferable to include feet and ankles also when evaluating remission.
‡ For the assessment of remission we suggest the following format and
wording for the global assessment questions. Format: a horizontal
10-cm visual analog or Likert scale with the best anchor and lowest
score on the left side and the worst anchor and highest score on the
right side. Wording of question and anchors: For patient global
assessment, “Considering all of the ways your arthritis has affected
you, how do you feel your arthritis is today?” (anchors: very well–very
poor). For physician/assessor global assessment, “What is your assess-
ment of the patient’s current disease activity?” (anchors: none–
extremely active).
§ Defined as the simple sum of the tender joint count (using 28 joints),
swollen joint count (using 28 joints), patient global assessment (0–10
scale), physician global assessment (0–10 scale), and C-reactive protein
level (mg/dl).
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to measure components of the definitions are also
provided.
DISCUSSION
Based on considerations of face and predictive
validity, the need for stringency, and the need to include
patient-reported outcomes, the ACR/EULAR commit-
tee charged with defining remission in RA has produced
two definitions for evaluating remission in clinical trials.
One is a Boolean-based definition, more categorical in
structure than the traditional definition from Pinals et al
(16), and the other is based on a composite index of RA
activity, the SDAI (19,51).
Ideally, we would have liked to select a candidate
definition that clearly differentiated patients whose
long-term course was without disease progression versus
those whose disease continued to progress. Our analysis
of long-term data confirmed the findings of our system-
atic review (30) that most definitions of remission did
well—i.e., that patients whose RA was in remission at
any point during a clinical trial, based on any of the
definitions we used, were likely to have long-term
courses that were better than those of patients who did
not meet the definition of remission. One exception was
the DAS28, which has been shown previously to allow
for significant residual disease activity (19,22,23,54,55).
Thus, except for DAS28-based definitions, differences in
predictive validity between candidate definitions were
small (see Tables 2 and 3), and it was difficult to
differentiate the course of patients meeting any of these
definitions of remission. Among the many definitions
tested, none importantly exceeded the ability of the
ultimately selected criteria to predict favorable long-
term effects on radiographic progression and physical
function. Although we can confirm the predictive valid-
ity of remission, the goal of the work was to define
remission, not to develop a predictive marker.
In our data sets we assessed definitions of remis-
sion by 28-joint counts. When we examined more com-
prehensive counts among patients with disease remission
in the 28 joints, we found that residual disease activity
was frequently present in ankles and feet. However,
most of these patients failed to meet other criteria in the
remission definition (e.g., their patient global assess-
ments were often high). In other words, even when joints
other than the 28 joints counted were swollen or tender,
other measures of disease activity often prevented mis-
classification of these patients as having disease in
remission. In addition, the impact of misclassification on
long-term outcome proved to be small. We should also
bear in mind that the assessment of ankles and forefeet
is particularly limited and poorly reproducible (56). In
line with this, the discordance between tenderness and
swelling has proved to be greater in the joints of the feet
than in other joints (57). Therefore, we do not require
inclusion of ankles and forefeet in the assessment of
remission but recommend that these joints are also
included in the examination. Investigators should always
report which joints were examined.
In 2008, EULAR and the ACR recommended
that in each RA trial, the percentage of patients achiev-
ing a low disease activity state and remission should be
reported (32,33). On the basis of the present analyses
and consensus, we suggest that remission based on one
of the definitions recommended here be reported as a
preselected outcome measure in trials, and that results
for both be included in trial reports. Of the approaches
to defining low disease activity, the OMERACT defini-
tions of “minimal disease activity,” designed to reflect
the “next best” option apart from remission, have been
the best vetted and were consensually developed (29).
There are a few limitations to our approach, and
possibly to the definitions produced as a consequence.
First, we used a HAQ score of 0.5 as evidence for
stability of the remission criteria; while this is a disability
score that is essentially above values obtained in the
general population (58), many of the studies evaluated
were of patients with longstanding disease who are known
to accumulate significant irreversible disability (59). How-
ever, we accounted for this potential contrast to the
normal situation by also requiring that HAQ scores did
not deteriorate at all over a full 1-year period (HAQ
change 0 during the second year of observation).
Second, we have not yet validated the recom-
mended definitions of remission in observational data
sets. This is the next step in our work. In developing
definitions, we anticipated clinic-based evaluations, try-
ing to choose definitions of remission that would be easy
to apply in an observational context and take advantage
of variables that are probably already being measured.
In clinical practice, data on acute-phase reactants are
frequently not immediately available, and therefore, an
additional set of a Boolean definition and an index-
based definition not requiring acute-phase reactants is
provided for that setting. Nevertheless, our preliminary
suggestions for defining remission in clinical practice are
still incomplete, as we did not test them in a clinic-based
setting. While the remission definitions not requiring
an acute-phase reactant performed comparably with
those that do require this parameter, the committee
believes that including an acute-phase reactant for re-
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porting remission in clinical trials is preferable because
acute-phase reactants are important predictors of later
radiographic damage (60–62).
Another limitation of the proposed definition is
that the patient experience of remission may not have
been adequately captured with only one element, the
patient’s global assessment of his or her disease activity.
Indeed, an index based on patient measures alone may
clinically discriminate between active and control treat-
ment as well as do some of the indexes tested in this
effort (63,64). However, the committee had stipulated
that joint counts should be part of the remission criteria;
moreover, joints are the “organ” involved in RA, and in
the context of assessing remission it was deemed advis-
able to assess that organ.
Further, fatigue was not evaluated (65). How-
ever, fatigue was not assessed in most trials published
over the last decade, including those used here for the
derivation of the remission criteria. We were also unable
to procure data sets that contained information on other
non–core set measures. As these data sets are likely to
become available only over the course of several years,
we decided not to postpone the development of the new
remission definition. Indeed, we believe it was important
to spend more time developing the concept of patient-
assessed “absence of disease.” This will require qualita-
tive research involving focus groups, as well as quanti-
tative research, e.g., collection of patient-related
outcome data in clinical trials, a task that will be taken
forward within the OMERACT framework. Once a
working definition of this concept is available, it can be
compared with the proposed definition of remission.
Yet another theoretical limitation is that imaging
results are not included in our definition of remission.
Our goal was to use clinical parameters that are widely
used and convenient to assess, but we recognize that
residual synovitis may exist in many patients whose
disease appears inactive based on conventional clinical
evaluation (55,66,67). Importantly, however, our defini-
tions of remission were associated with a retardation of
radiographic progression, suggesting that the clinical
definition has biologic meaning. Moreover, findings of a
recent sonographic analysis of RA patients whose dis-
ease was in remission as defined by different means (55)
were in accordance with the present results. Thus, while
our definitions permit a tender or swollen joint to be
present, we require multiple pieces of evidence of in-
active disease (1 or no tender or swollen joint, low
acute-phase reactant level, and assessment by the pa-
tient that the disease is inactive) before a patient meets
remission criteria. Since inactive disease may be accom-
panied by 1 residual swollen or tender joint and since the
reliability of the examination diminishes with the num-
ber of joints with active disease, this procedure enhances
the sensitivity of our definition of remission.
We should note that the trial data sets we tested
included CRP more frequently than erythrocyte sedi-
mentation rate (ESR), explaining why our definitions
present thresholds for CRP. A similar ESR threshold for
inactive disease might be 20 mm/hour for men and
30 mm/hour for women, or even lower, but this may
require further testing (68). Our preference for CRP is
in part because it can be standardized across centers,
making it the preferred acute-phase reactant measure in
multicenter trials. Also, while CRP levels may have
different upper limits of normal in different laboratories,
the test is widely standardized today, and a value of 1
mg/dl covers all of these upper limits; at 1 mg/dl or less
the progression of joint damage is minimized (60,61).
Given these findings, the practicality of using the same
value, i.e., 1, for all measures was deemed more impor-
tant than searching for potential minimal differences
between cut points of 1 mg/dl or slightly less.
A “treat to target” approach may yield better
outcomes than a conventional approach to therapy for
RA, and remission can serve as that target for some
patients. However, remission according to the stringent
definition presented here may not yet be a realistic goal
for most patients (10).
In conclusion, we present new definitions of
remission for use as outcome measures in RA clinical
trials: either the compilation of 4 individual measures or
an index-based alternative. We hope that these new
definitions will be adopted widely and can provide a
uniform approach to assessing this increasingly impor-
tant outcome.
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